Publications by authors named "A Zayac"
Article Synopsis
- There is limited knowledge about the risk of central nervous system (CNS) involvement in high-grade B-cell lymphoma, not otherwise specified (HGBL NOS), prompting a study that assessed baseline CNS involvement, recurrence rates, and management strategies in patients treated from 2016 to 2021.
- In the study of 160 adults, 7% exhibited baseline CNS involvement, which was linked to MYC rearrangement and certain sites of involvement, but did not significantly impact overall survival outcomes compared to those without CNS involvement.
- The risk of CNS recurrence within three years was found to be 11%, with patients showing initial CNS involvement facing a much higher risk (48.5%), while various other factors such as blood involvement and
Article Synopsis
- A study analyzed 160 patients with high-grade B-cell lymphoma (HGBL-NOS), a rare type of lymphoma, showing that it has diverse characteristics with varying gene rearrangements and immunophenotypes among patients.
- Most patients presented with advanced disease and were treated with several chemotherapy regimens, including DA-EPOCH-R and R-CHOP, but there was no significant difference in treatment effectiveness regarding complete response or survival rates.
- Key factors predicting poorer outcomes included poor performance status and high lactate dehydrogenase levels, while improvements in diagnostic and treatment methods are needed to enhance prognosis for HGBL-NOS patients.
There is a paucity of large-scale data delineating outcomes and prognostication of older patients with primary central nervous system lymphoma (PCNSL). We retrospectively analyzed 539 newly-diagnosed PCNSL patients ages ≥60 years across 20 U.S.
View Article and Find Full Text PDFThe objective of this multicenter retrospective study was to examine the incidence, patient characteristics, pathology, and outcomes associated with Epstein-Barr virus (EBV)-related CNS lymphoma (CNSL) in older patients. Among 309 CNSL patients aged ≥60, 11.7% had EBV + tumors of which 72.
View Article and Find Full Text PDFBackground: Patients with hematologic malignancies have impaired humoral immunity secondary to their malignancy and its treatment, placing them at risk of severe coronavirus disease-19 (COVID-19) infection and reduced response to vaccination.
Methods: The authors retrospectively analyzed serologic responses to initial and booster COVID-19 vaccination in 378 patients with hematologic malignancy and subsequently tracked COVID-19-related outcomes.
Results: Seroconversion occurred in 181 patients (48%) after initial vaccination; patients who had active malignancy or those who were recently treated with a B-cell-depleting monoclonal antibody had the lowest rates of seroconversion.